EUVIMEDEUVIMED entdecken
VergleichsstudieÄquivalenzstudieMultizentrische StudieRandomisierte kontrollierte StudieOpen Access · CC BY-NC-ND 4.0

Sirolimus-Eluting Balloon vs Repeat Drug-Eluting Stent or Balloon Angioplasty for Coronary In-Stent Restenosis

Donald E Cutlip, Roxana Mehran, Samin Sharma, Gheorghe Doros, Brian Jefferson, Giulio Stefanini, Suhail Dohad, Antoinette Neylon, Itsik Ben-Dor, Dwijesh Patel, Bassem M Chehab, Anay Pradhan und 7 weitere

JACC · 2026-07 · 88 (1) · 62-72

DOI: 10.1016/j.jacc.2026.03.021 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift JACC, 2026-07. Verfasst von Donald E Cutlip und 18 weiteren Autor:innen. Beteiligte Einrichtung: Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA; Baim Institute for Clinical Research, Boston, Massachusetts…. Hauptthemen laut MEDLINE: Angioplasty, Balloon, Coronary, Coronary Restenosis, Drug-Eluting Stents, Sirolimus. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Cordis Corporation, U.S. Food and Drug Administration.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Drug-eluting stents (DESs) are recommended treatment for coronary in-stent restenosis (ISR) but are not used in >20% of cases. OBJECTIVES: The aim of the SELUTION4ISR (SELUTION SLR 014 In-stent Restenosis) trial was to assess the safety and effectiveness of a novel sirolimus drug-eluting balloon (DEB). METHODS: After successful lesion predilation, patients with ISR were randomly assigned to the SELUTION Sustained Limus Release (MedAlliance) DEB or a control strategy of usual care, including any approved DES or balloon angioplasty (BA) on the basis of operator selection prerandomization. Randomization to selected BA control treatment was limited to 20% of patients. The primary outcome was target lesion failure (TLF) (cardiac death, target vessel myocardial infarction, or clinically driven target lesion revascularization) assessed at 1 year in the per protocol group (all treated eligible patients with complete primary endpoint follow-up). Noninferiority was established if the upper limit of the 2-sided 95% credible interval was smaller than 10%. A sequential secondary hypothesis test was performed comparing DEB with DES in patients with single-layer ISR. RESULTS: From July 2020 to July 2024, 418 patients were randomly assigned to the DEB group (n = 210) or the control group (n = 208), with 390 patients per protocol (DEB, 197; control, 193 [154 DES; 39 BA]). TLF occurred in 32 (16.2%) of 197 patients in the DEB group and in 28 (14.5%) of 193 patients in the control group (difference: 1.7%; 95% credible interval: -5.5% to 8.9%; posterior probability of noninferiority: 98.80%). In the secondary hypothesis test, TLF occurred in 22 (14.2%) of 155 patients in the DEB group and in 9 (6.5%) of 138 patients in the DES control group (difference: 7.7%; 95% credible interval: 0.6%-14.6%, posterior probability for noninferiority: 76.07%). TLF according to operator selected control was higher for DEB compared with DES (15.3% vs 7.1%; difference: 8.1%; 95% credible interval: 1.4%-15.0%) and lower for DEB compared with BA (23.6% vs 43.6%; difference: 23.7%; 95% credible interval: -41.4% to -1.5%; Pforinteraction = 0.0026). CONCLUSIONS: The sirolimus DEB was noninferior to a usual care control strategy including 80% repeat DES but not noninferior to DES for single-layer ISR for TLF at 12 months. There was significant interaction on the basis of operator selection of DES vs BA. (SELUTION SLR 014 In-stent Restenosis [SELUTION4ISR]; NCT04280029).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Angioplasty, Balloon, CoronaryCoronary RestenosisDrug-Eluting StentsSirolimusAgedFemaleHumansMaleMiddle AgedTreatment Outcome

Stichwörter der Autor:innen

coronary stentdrug-coated balloonrestenosis

Substanzen

Sirolimus

Autor:innen und Institutionen

  • Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA; Baim Institute for Clinical Research, Boston, Massachusetts, USA. Electronic address: dcutlip@bidmc.harvard.edu.
  • Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
  • Baim Institute for Clinical Research, Boston, Massachusetts, USA; Boston University School of Public Health, Boston, Massachusetts, USA.
  • HCA TriStar Centennial Medical Center, Nashville, Tennessee, USA.
  • Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy; Cardio Center, Scientific Institute for Research, Hospitalization, and Health Care Humanitas Research Hospital, Rozzano, Milan, Ital…
  • Cedars-Sinai Medical Group and Cedars-Sinai Heart Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA.

Förderung

  • Cordis Corporation
  • U.S. Food and Drug Administration

Zitieren

APA

Cutlip, D. E., Mehran, R., Sharma, S., Doros, G., Jefferson, B., Stefanini, G., Dohad, S., Neylon, A., Ben-Dor, I., Patel, D., Chehab, B. M., Pradhan, A., Nerla, R., Vranckx, P., Poulin, M. F., Jeremias, A., Osborn, E. A., Waksman, R., & SELUTION4ISR Investigators (2026). Sirolimus-Eluting Balloon vs Repeat Drug-Eluting Stent or Balloon Angioplasty for Coronary In-Stent Restenosis. JACC, 88(1), 62-72. https://doi.org/10.1016/j.jacc.2026.03.021

Vancouver

Cutlip DE, Mehran R, Sharma S, Doros G, Jefferson B, Stefanini G, et al. Sirolimus-Eluting Balloon vs Repeat Drug-Eluting Stent or Balloon Angioplasty for Coronary In-Stent Restenosis. JACC. 2026;88(1):62-72. doi:10.1016/j.jacc.2026.03.021

BibTeX
@article{Cutlip2026,
  author = {Cutlip, Donald E and Mehran, Roxana and Sharma, Samin and Doros, Gheorghe and Jefferson, Brian and Stefanini, Giulio and Dohad, Suhail and Neylon, Antoinette and Ben-Dor, Itsik and Patel, Dwijesh and Chehab, Bassem M and Pradhan, Anay and Nerla, Roberto and Vranckx, Pascal and Poulin, Marie-France and Jeremias, Allen and Osborn, Eric A and Waksman, Ron and SELUTION4ISR Investigators, SELUTION4ISR Investigators},
  title = {Sirolimus-Eluting Balloon vs Repeat Drug-Eluting Stent or Balloon Angioplasty for Coronary In-Stent Restenosis},
  journal = {JACC},
  year = {2026},
  volume = {88},
  number = {1},
  pages = {62--72},
  doi = {10.1016/j.jacc.2026.03.021}
}
Kostenlos starten →